Ownership Submission
FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
NovaQuest Pharma Opportunities Fund III, L.P.
  2. Issuer Name and Ticker or Trading Symbol
Revance Therapeutics, Inc. [RVNC]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director __X__ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
(Last)
(First)
(Middle)
4208 SIX FORKS ROAD, SUITE 920
3. Date of Earliest Transaction (Month/Day/Year)
02/11/2014
(Street)

RALEIGH, NC 27609
4. If Amendment, Date Original Filed(Month/Day/Year)
6. Individual or Joint/Group Filing(Check Applicable Line)
___ Form filed by One Reporting Person
_X_ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)
7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 02/11/2014   C   2,039,382 (1) A (2) 2,039,382 I by NovaQuest Pharma Opportunities Fund III, L.P. (3)
Common Stock 02/11/2014   C   658,551 (4) A (4) 2,697,933 I by NovaQuest Pharma Opportunities Fund III, L.P. (3)
Common Stock 02/11/2014   X   398,717 (5) A (5) 3,096,650 I by NovaQuest Pharma Opportunities Fund III, L.P. (3)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)
6. Date Exercisable and Expiration Date
(Month/Day/Year)
7. Title and Amount of Underlying Securities
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)
11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Series E-4 Convertible Preferred Stock (2) 02/11/2014   C     1,539,343   (2)   (2) Common Stock 1,539,343 (2) 0 I by NovaQuest Pharma Opportunities Fund III, L.P. (3)
Series E-5 Convertible Preferred Stock (2) 02/11/2014   C     500,039   (2)   (2) Common Stock 500,039 (2) 0 I by NovaQuest Pharma Opportunities Fund III, L.P. (3)
Convertible Promissory Notes (4) 02/11/2014   C     658,551 (4)   (4)   (4) Common Stock 658,551 (4) (4) 0 I by NovaQuest Pharma Opportunities Fund III, L.P. (3)
Warrant to Purchase Common Stock (6) 02/11/2014   X     398,717 (7)   (6)   (6) Common Stock 398,717 (7) (6) 0 I by NovaQuest Pharma Opportunities Fund III, L.P. (3)

Reporting Owners

Reporting Owner Name / Address Relationships
 Director  10% Owner  Officer  Other
NovaQuest Pharma Opportunities Fund III, L.P.
4208 SIX FORKS ROAD, SUITE 920
RALEIGH, NC 27609
    X    
NQ HCIF General Partner, L.P.
4208 SIX FORKS ROAD, SUITE 920
RALEIGH, NC 27609
    X    
NQ HCIF GP, Ltd.
4208 SIX FORKS ROAD, SUITE 920
RALEIGH, NC 27609
    X    

Signatures

 /s/ Gordon Ho, Attorney-in-fact   02/11/2014
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Issued upon conversion of Series E-4 and E-5 Preferred Stock upon closing of the Issuer's initial public offering.
(2) Each share of the Issuer's Series E-1, Series E-2, Series E-3, Series E-4 and Series E-5 Preferred Stock automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering and has no expiration date.
(3) These securities are held by NovaQuest Pharma Opportunities Fund III, L.P. ("NovaQuest"). NQ HCIF General Partner, L.P., the general partner of NovaQuest ("NovaQuest GP"), has the power to vote and dispose of securities directly owned by NovaQuest, and NQ HCIF GP, Ltd., the general partner of NovaQuest GP ("NovaQuest GP Ltd."), has the power to direct the NovaQuest GP as to such voting and disposition. NovaQuest GP Ltd.'s investment committee makes voting and investment decisions regarding securities held by NovaQuest. NovaQuest GP and NovaQuest GP Ltd each disclaims beneficial ownership of the securities held by NovaQuest except to the extent of its pecuniary interest therein.
(4) Convertible Promissory Notes in the aggregate principal amount of $9,500,000.00 were issued between October 8, 2013 and January 16, 2014 by the Issuer pursuant to a Note and Warrant Purchase Agreement dated October 8, 2013, as amended. The principal amount of $9,500,000.00 plus interest accrued through October 7, 2014, at the rate of 12% per annum converted automatically upon the closing of the Issuer's initial public offering into shares of Common Stock at a conversion price that equals to 100% of the per share price of the Common Stock sold in the Issuer's initial public offering.
(5) Issued upon closing of the Issuer's initial public offering pursuant to automatic net exercise of warrants to purchase common stock at an exercise price of $0.15 per share.
(6) Automatically net exercised into shares of the Issuer's Common Stock at an exercise price of $0.15 per share.
(7) Includes certain warrants to purchase capital stock of the Issuer issued between October 8, 2013 and January 16, 2014 by the Issuer pursuant to a Note and Warrant Purchase Agreement dated October 8, 2013, as amended. The warrant shares were automatically net exercised into Common Stock of the Issuer upon the closing of the Issuer's initial public offering at a per share exercise price of $0.15 per share on a post-split basis.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.